{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T14:46:33Z","timestamp":1775486793728,"version":"3.50.1"},"reference-count":99,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T00:00:00Z","timestamp":1731715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014677","name":"George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures Research","doi-asserted-by":"publisher","award":["10127\/6\/17.12.2020"],"award-info":[{"award-number":["10127\/6\/17.12.2020"]}],"id":[{"id":"10.13039\/501100014677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Despite the discovery of antibiotics, bacterial infections persist globally, exacerbated by rising antimicrobial resistance that results in millions of cases, increased healthcare costs, and more extended hospital stays. The urgent need for new antibacterial drugs continues as resistance evolves. Fluoroquinolones and tetracyclines are versatile antibiotics that are effective against various bacterial infections. A hybrid antibiotic combines two or more molecules to enhance antimicrobial effectiveness and combat resistance better than monotherapy. Fluoroquinolones are ideal candidates for hybridization due to their potent bactericidal effects, ease of synthesis, and ability to form combinations with other molecules. Methods: This study explored the mechanisms of action for 40 hypothetical fluoroquinolone\u2013tetracycline hybrids, all of which could be obtained using a simple, eco-friendly synthesis method. Their interaction with Escherichia coli DNA Gyrase and similarity to albicidin were evaluated using the FORECASTER platform. Results: Hybrids such as Do-Ba, Mi-Fi, and Te-Ba closely resembled albicidin in physicochemical properties and FITTED Scores, while Te-De surpassed it with a better score. Similar to fluoroquinolones, these hybrids likely inhibit DNA synthesis by binding to enzyme\u2013DNA complexes. Conclusions: These hybrids could offer broad-spectrum activity and help mitigate bacterial resistance, though further in vitro and in vivo studies are needed to validate their potential.<\/jats:p>","DOI":"10.3390\/ph17111540","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T05:36:45Z","timestamp":1731908205000},"page":"1540","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["In Silico Study of the Potential Inhibitory Effects on Escherichia coli DNA Gyrase of Some Hypothetical Fluoroquinolone\u2013Tetracycline Hybrids"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0909-0762","authenticated-orcid":false,"given":"Ioana-Andreea","family":"Lungu","sequence":"first","affiliation":[{"name":"Medicine and Pharmacy Doctoral School, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9333-4063","authenticated-orcid":false,"given":"Octavia-Laura","family":"Oancea","sequence":"additional","affiliation":[{"name":"Organic Chemistry Department, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4979-6903","authenticated-orcid":false,"given":"Aura","family":"Rusu","sequence":"additional","affiliation":[{"name":"Pharmaceutical and Therapeutic Chemistry Department, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,16]]},"reference":[{"key":"ref_1","unstructured":"(2022, July 26). Hospital-Acquired Complication\u20143. Healthcare-Associated Infection Fact Sheet|Australian Commission on Safety and Quality in Health Care, Available online: https:\/\/www.safetyandquality.gov.au\/publications-and-resources\/resource-library\/hospital-acquired-complication-3-healthcare-associated-infection-fact-sheet."},{"key":"ref_2","unstructured":"(2022, March 16). Global Guidelines for the Prevention of Surgical Site Infection, 2nd Ed. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789241550475."},{"key":"ref_3","unstructured":"CDC (2023, February 12). The Biggest Antibiotic-Resistant Threats in the U.S, Available online: https:\/\/www.cdc.gov\/antimicrobial-resistance\/data-research\/threats\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/drugresistance\/biggest-threats.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1093\/cid\/ciaa1581","article-title":"National Estimates of Healthcare Costs Associated With Multidrug-Resistant Bacterial Infections Among Hospitalized Patients in the United States","volume":"72","author":"Nelson","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1057\/s41599-018-0181-x","article-title":"The Evolving Response to Antibiotic Resistance (1945\u20132018)","volume":"4","author":"Podolsky","year":"2018","journal-title":"Palgrave Commun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.bcp.2016.09.025","article-title":"Antibiotics in Late Clinical Development","volume":"133","author":"Fernandes","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"ref_7","first-page":"25","article-title":"Antibiotics and Bacterial Resistance in the 21st Century","volume":"6","author":"Fair","year":"2014","journal-title":"Perspect. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Skandalis, N., Maeusli, M., Papafotis, D., Miller, S., Lee, B., Theologidis, I., and Luna, B. (2021). Environmental Spread of Antibiotic Resistance. Antibiotics, 10.","DOI":"10.3390\/antibiotics10060640"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e01326-19","DOI":"10.1128\/AAC.01326-19","article-title":"Novel Plasmid-Mediated Tet(X5) Gene Conferring Resistance to Tigecycline, Eravacycline, and Omadacycline in a Clinical Acinetobacter Baumannii Isolate","volume":"64","author":"Wang","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.survophthal.2004.01.005","article-title":"Fluoroquinolones: Mechanism of Action, Classification, and Development of Resistance","volume":"49","author":"Blondeau","year":"2004","journal-title":"Surv. Ophthalmol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1751-7915.2008.00063.x","article-title":"Mechanism of Action of and Resistance to Quinolones","volume":"2","author":"Madurga","year":"2009","journal-title":"Microb. Biotechnol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1021\/bi5000564","article-title":"Mechanism of Quinolone Action and Resistance","volume":"53","author":"Aldred","year":"2014","journal-title":"Biochemistry"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1099\/jmm.0.000475","article-title":"Mechanisms of Quinolone Action and Resistance: Where Do We Stand?","volume":"66","author":"Correia","year":"2017","journal-title":"J. Med. Microbiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1099\/00222615-44-5-320","article-title":"Quinolones: Structure-Activity Relationships and Future Predictions","volume":"44","author":"Tillotson","year":"1996","journal-title":"J. Med. Microbiol."},{"key":"ref_15","first-page":"587","article-title":"Fluoroquinolone Antibacterials: A Review on Chemistry, Microbiology and Therapeutic Prospects","volume":"66","author":"Sharma","year":"2009","journal-title":"Acta Pol. Pharm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jpba.2012.02.024","article-title":"Triprotic Site-Specific Acid\u2013Base Equilibria and Related Properties of Fluoroquinolone Antibacterials","volume":"66","author":"Rusu","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejps.2016.07.016","article-title":"Solubility, Lipophilicity and Membrane Permeability of Some Fluoroquinolone Antimicrobials","volume":"93","author":"Blokhina","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Millanao, A.R., Mora, A.Y., Villagra, N.A., Bucarey, S.A., and Hidalgo, A.A. (2021). Biological Effects of Quinolones: A Family of Broad-Spectrum Antimicrobial Agents. Molecules, 26.","DOI":"10.3390\/molecules26237153"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Rusu, A., Lungu, I.-A., Moldovan, O.-L., Tanase, C., and Hancu, G. (2021). Structural Characterization of the Millennial Antibacterial (Fluoro)Quinolones\u2014Shaping the Fifth Generation. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13081289"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Bush, N.G., Diez-Santos, I., Abbott, L.R., and Maxwell, A. (2020). Quinolones: Mechanism, Lethality and Their Contributions to Antibiotic Resistance. Molecules, 25.","DOI":"10.3390\/molecules25235662"},{"key":"ref_21","unstructured":"Horta, P., Secrieru, A., Coninckx, A., and Cristiano, M. (2018). Quinolones for Applications in Medicinal Chemistry: Synthesis and Structure in Targets in Heterocyclic Systems\u20142018, Chapter 11; Italian Chemical Society."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0025-7125(16)30039-6","article-title":"Tetracyclines","volume":"79","author":"Klein","year":"1995","journal-title":"Med. Clin. North Am."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1128\/MMBR.65.2.232-260.2001","article-title":"Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance","volume":"65","author":"Chopra","year":"2001","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1128\/AAC.00594-16","article-title":"rRNA Binding Sites and the Molecular Mechanism of Action of the Tetracyclines","volume":"60","author":"Chukwudi","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jac\/dkm307","article-title":"Minocycline Inhibits West Nile Virus Replication and Apoptosis in Human Neuronal Cells","volume":"60","author":"Michaelis","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.2174\/1874467214666210210122628","article-title":"Minocycline and Doxycycline: More Than Antibiotics","volume":"14","author":"Singh","year":"2021","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Debrah, A.Y., Mand, S., Specht, S., Marfo-Debrekyei, Y., Batsa, L., Pfarr, K., Larbi, J., Lawson, B., Taylor, M., and Adjei, O. (2006). Doxycycline Reduces Plasma VEGF-C\/sVEGFR-3 and Improves Pathology in Lymphatic Filariasis. PLoS Pathog., 2.","DOI":"10.1371\/journal.ppat.0020092"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3810\/pgm.2010.01.2107","article-title":"A Review of the Diagnosis and Treatment of Rosacea","volume":"122","author":"Scheinfeld","year":"2010","journal-title":"Postgrad. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1086\/651277","article-title":"Minocycline Attenuates HIV Infection and Reactivation by Suppressing Cellular Activation in Human CD4+ T Cells","volume":"201","author":"Szeto","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_30","first-page":"467","article-title":"Use of Minocycline in Viral Infections","volume":"133","author":"Dutta","year":"2011","journal-title":"Indian J. Med. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1592\/phco.26.4.515","article-title":"Minocycline for Acute Neuroprotection","volume":"26","author":"Elewa","year":"2006","journal-title":"Pharmacotherapy"},{"key":"ref_32","unstructured":"Shutter, M.C., and Akhondi, H. (2022). Tetracycline. StatPearls, StatPearls Publishing."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1080\/07853890.2022.2085881","article-title":"Re-Establishing the Utility of Tetracycline-Class Antibiotics for Current Challenges with Antibiotic Resistance","volume":"54","author":"LaPlante","year":"2022","journal-title":"Ann. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/ijmr.IJMR_755_18","article-title":"Next-Generation Strategy for Treating Drug Resistant Bacteria: Antibiotic Hybrids","volume":"149","author":"Gupta","year":"2019","journal-title":"Indian J. Med. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.coph.2008.06.008","article-title":"How Many Modes of Action Should an Antibiotic Have?","volume":"8","author":"Brunner","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1517\/17460441.2010.508069","article-title":"Dual-Acting Hybrid Antibiotics: A Promising Strategy to Combat Bacterial Resistance","volume":"5","author":"Pokrovskaya","year":"2010","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/jac\/dkg208","article-title":"The Quinolones: Decades of Development and Use","volume":"51","author":"Emmerson","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_38","first-page":"207","article-title":"The New Fluoroquinolones: A Critical Review","volume":"10","author":"Zhanel","year":"1999","journal-title":"Can. J. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.tim.2014.04.007","article-title":"Fluoroquinolone Resistance: Mechanisms, Impact on Bacteria, and Role in Evolutionary Success","volume":"22","author":"Redgrave","year":"2014","journal-title":"Trends Microbiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkg212","article-title":"Development of the Quinolones","volume":"51","author":"Andersson","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Limberakis, C. (2007). Quinolone Antibiotics: Levofloxacin (Levaquin\u00ae), Moxifloxacin (Avelox\u00ae), Gemifloxacin (Factive\u00ae), and Garenoxacin (T-3811). The Art of Drug Synthesis, John Wiley & Sons, Ltd.","DOI":"10.1002\/9780470134979.ch4"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"11153","DOI":"10.3390\/molecules180911153","article-title":"Metal Complexes of Quinolone Antibiotics and Their Applications: An Update","volume":"18","author":"Uivarosi","year":"2013","journal-title":"Molecules"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.ejmech.2018.08.095","article-title":"Recent Developments of Quinolone-Based Derivatives and Their Activities against Escherichia Coli","volume":"157","author":"Gao","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00706-018-2215-x","article-title":"Modifications of Quinolones and Fluoroquinolones: Hybrid Compounds and Dual-Action Molecules","volume":"149","author":"Fedorowicz","year":"2018","journal-title":"Monatshefte Chem."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Lungu, I.-A., Moldovan, O.-L., Biri\u0219, V., and Rusu, A. (2022). Fluoroquinolones Hybrid Molecules as Promising Antibacterial Agents in the Fight against Antibacterial Resistance. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14081749"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.bmcl.2006.11.055","article-title":"Newer Tetracycline Derivatives: Synthesis, Anti-HIV, Antimycobacterial Activities and Inhibition of HIV-1 Integrase","volume":"17","author":"Sriram","year":"2007","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1021\/jm900028n","article-title":"Design, Synthesis, and Evaluation of Novel Fluoroquinolone\u2212Aminoglycoside Hybrid Antibiotics","volume":"52","author":"Pokrovskaya","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"8441","DOI":"10.1021\/acs.jmedchem.6b00867","article-title":"Hybrid Antibiotic Overcomes Resistance in P. Aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux","volume":"59","author":"Gorityala","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1016\/j.bmcl.2003.07.021","article-title":"Novel Oxazolidinone-Quinolone Hybrid Antimicrobials","volume":"13","author":"Gordeev","year":"2003","journal-title":"Bioorganic Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4066\/AMJ.2015.2441","article-title":"Cadazolid: A New Hope in the Treatment of Clostridium Difficile Infection","volume":"8","author":"Kali","year":"2015","journal-title":"Australas. Med. J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1473-3099(18)30614-5","article-title":"Cadazolid for the Treatment of Clostridium Difficile Infection: Results of Two Double-Blind, Placebo-Controlled, Non-Inferiority, Randomised Phase 3 Trials","volume":"19","author":"Gerding","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejmech.2016.03.086","article-title":"Synthesis and Biological Evaluation of Novel Structural Hybrids of Benzofuroxan Derivatives and Fluoroquinolones","volume":"116","author":"Chugunova","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/cmdc.201700739","article-title":"Discovery of Benzimidazole-Quinolone Hybrids as New Cleaving Agents toward Drug-Resistant Pseudomonas Aeruginosa DNA","volume":"13","author":"Wang","year":"2018","journal-title":"ChemMedChem"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41429-019-0228-2","article-title":"Albicidin, a Potent DNA Gyrase Inhibitor with Clinical Potential","volume":"72","author":"Hashimi","year":"2019","journal-title":"J. Antibiot."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1039\/B918763B","article-title":"Green Chemistry: Principles and Practice","volume":"39","author":"Anastas","year":"2010","journal-title":"Chem. Soc. Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"100044","DOI":"10.1016\/j.crgsc.2020.100044","article-title":"Green Chemistry Approaches towards the Design and Synthesis of Anti-Infective Fluoroquinolone Derivatives","volume":"4","author":"Goyal","year":"2021","journal-title":"Curr. Res. Green Sustain. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1086\/319370","article-title":"Mechanisms of Action of Antimicrobials: Focus on Fluoroquinolones","volume":"32","author":"Hooper","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"a025320","DOI":"10.1101\/cshperspect.a025320","article-title":"Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance","volume":"6","author":"Hooper","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41929-022-00904-1","article-title":"Molecular Mechanism of Topoisomerase Poisoning by the Peptide Antibiotic Albicidin","volume":"6","author":"Michalczyk","year":"2023","journal-title":"Nat. Catal."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1359-6446(02)02483-2","article-title":"Structure-Based Virtual Screening: An Overview","volume":"7","author":"Lyne","year":"2002","journal-title":"Drug Discov. Today"},{"key":"ref_61","first-page":"453","article-title":"Screening for Drug Discovery: The Leading Question","volume":"418","author":"Smith","year":"2002","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1021\/ci200528d","article-title":"Recognizing Pitfalls in Virtual Screening: A Critical Review","volume":"52","author":"Scior","year":"2012","journal-title":"J. Chem. Inf. Model."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13321-021-00506-2","article-title":"Analysis of the Effects of Related Fingerprints on Molecular Similarity Using an Eigenvalue Entropy Approach","volume":"13","author":"Kuwahara","year":"2021","journal-title":"J. Cheminformatics"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"012015","DOI":"10.1088\/1742-6596\/892\/1\/012015","article-title":"Similarity Measure for Molecular Structure: A Brief Review","volume":"892","author":"Bero","year":"2017","journal-title":"J. Phys. Conf. Ser."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Bajorath, J. (2011). Similarity Searching Using 2D Structural Fingerprints. Chemoinformatics and Computational Chemical Biology, Humana Press.","DOI":"10.1007\/978-1-60761-839-3"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.drudis.2006.10.005","article-title":"Similarity-Based Virtual Screening Using 2D Fingerprints","volume":"11","author":"Willett","year":"2006","journal-title":"Drug Discov. Today"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ymeth.2014.08.005","article-title":"Molecular Fingerprint Similarity Search in Virtual Screening","volume":"71","author":"Ojeda","year":"2015","journal-title":"Methods"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1021\/ci010132r","article-title":"Reoptimization of MDL Keys for Use in Drug Discovery","volume":"42","author":"Durant","year":"2002","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1016\/j.csbj.2021.08.011","article-title":"A Review on Machine Learning Approaches and Trends in Drug Discovery","volume":"19","author":"Novoa","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.yrtph.2018.11.002","article-title":"Molecular Fingerprint-Derived Similarity Measures for Toxicological Read-across: Recommendations for Optimal Use","volume":"101","author":"Mellor","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1021\/jm020155c","article-title":"Do Structurally Similar Molecules Have Similar Biological Activity?","volume":"45","author":"Martin","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"W55","DOI":"10.1093\/nar\/gkn307","article-title":"SuperPred: Drug Classification and Target Prediction","volume":"36","author":"Dunkel","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"ref_73","first-page":"83","article-title":"Making Big Sense from Big Data in Toxicology by Read-Across","volume":"33","author":"Hartung","year":"2016","journal-title":"ALTEX\u2014Altern. Anim. Exp."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and Drug-like Compounds: The Rule-of-Five Revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"key":"ref_76","unstructured":"Velmourougane, G. (2024, November 11). Understanding Lipinski\u2019s Rule of 5 and the Role of LogP Value in Drug Design and Development. Available online: https:\/\/www.sailife.com\/understanding-lipinskis-rule-of-5-and-the-role-of-logp-value-in-drug-design-and-development\/."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Roy, D., and Patel, C. (2023). Revisiting the Use of Quantum Chemical Calculations in LogPoctanol-Water Prediction. Molecules, 28.","DOI":"10.3390\/molecules28020801"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0169-409X(02)00008-X","article-title":"Prediction of Drug Solubility from Structure","volume":"54","author":"Jorgensen","year":"2002","journal-title":"Advanced Drug Delivery Reviews"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Romanick, M., and Holt, A. (2023). Topological Polar Surface Area. An ABC of PK\/PD. Core Concepts in Pharmacokinetics and Pharmacodynamics for Students of Medicine, Dentistry and Pharmacy, University of Alberta Library. Available online: https:\/\/pressbooks.openeducationalberta.ca\/abcofpkpd\/chapter\/tpsa\/.","DOI":"10.29173\/oer41"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","article-title":"Medicinal Chemical Properties of Successful Central Nervous System Drugs","volume":"2","author":"Pajouhesh","year":"2005","journal-title":"Neurotherapeutics"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"7559","DOI":"10.1021\/jm060642i","article-title":"Structure\u2212Brain Exposure Relationships","volume":"49","author":"Hitchcock","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Arteca, G.A. (1996). Molecular Shape Descriptors. Reviews in Computational Chemistry, John Wiley & Sons, Ltd.","DOI":"10.1002\/9780470125861.ch5"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Kufareva, I., and Abagyan, R. (2012). Methods of Protein Structure Comparison. Methods Mol. Biol., 857.","DOI":"10.1007\/978-1-61779-588-6_10"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Ram\u00edrez, D., and Caballero, J. (2018). Is It Reliable to Take the Molecular Docking Top Scoring Position as the Best Solution without Considering Available Structural Data?. Molecules, 23.","DOI":"10.3390\/molecules23051038"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"20200007","DOI":"10.1098\/rsfs.2020.0007","article-title":"Rapid, Accurate, Precise and Reproducible Ligand\u2013Protein Binding Free Energy Prediction","volume":"10","author":"Wan","year":"2020","journal-title":"Interface Focus"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1128\/AAC.01651-07","article-title":"In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Microbiology Profiling Studies with Staphylococci and Streptococci","volume":"52","author":"Robertson","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_87","unstructured":"(2021, June 27). BIOVIA Draw 2021. Available online: https:\/\/www.3ds.com\/products\/biovia\/draw."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The Protein Data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Berman, H., Henrick, K., and Nakamura, H. (2003). Announcing the Worldwide Protein Data Bank. Nat. Struct. Mol. Biol., 10.","DOI":"10.1038\/nsb1203-980"},{"key":"ref_90","unstructured":"(2024, January 03). BIOVIA Discovery Studio 2024. Available online: https:\/\/www.3ds.com\/products\/biovia\/discovery-studio."},{"key":"ref_91","unstructured":"(2024, June 02). Forecaster. Available online: https:\/\/molecularforecaster.com\/academic-license\/."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1021\/ci2004779","article-title":"Integrating Medicinal Chemistry, Organic\/Combinatorial Chemistry, and Computational Chemistry for the Discovery of Selective Estrogen Receptor Modulators with Forecaster, a Novel Platform for Drug Discovery","volume":"52","author":"Therrien","year":"2012","journal-title":"J. Chem. Inf. Model."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1021\/acs.accounts.6b00185","article-title":"Medicinal Chemistry Projects Requiring Imaginative Structure-Based Drug Design Methods","volume":"49","author":"Moitessier","year":"2016","journal-title":"Acc. Chem. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jmgm.2015.01.009","article-title":"Comparing Sixteen Scoring Functions for Predicting Biological Activities of Ligands for Protein Targets","volume":"57","author":"Xu","year":"2015","journal-title":"J. Mol. Graph. Model."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1021\/acs.jcim.8b00228","article-title":"Comparative Evaluation of Covalent Docking Tools","volume":"58","author":"Scarpino","year":"2018","journal-title":"J. Chem. Inf. Model."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41929-020-0468-3","article-title":"From Desktop to Benchtop with Automated Computational Workflows for Computer-Aided Design in Asymmetric Catalysis","volume":"3","author":"Pottel","year":"2020","journal-title":"Nat. Catal."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1021\/acs.jcim.1c00701","article-title":"Docking Ligands into Flexible and Solvated Macromolecules. 8. Forming New Bonds\u2500Challenges and Opportunities","volume":"62","author":"Labarre","year":"2022","journal-title":"J. Chem. Inf. Model."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/ci6002637","article-title":"Docking Ligands into Flexible and Solvated Macromolecules. 1. Development and Validation of FITTED 1.0","volume":"47","author":"Corbeil","year":"2007","journal-title":"J. Chem. Inf. Model."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1021\/ci400550m","article-title":"Docking Ligands into Flexible and Solvated Macromolecules. 6. Development and Application to the Docking of HDACs and Other Zinc Metalloenzymes Inhibitors","volume":"54","author":"Pottel","year":"2014","journal-title":"J. Chem. Inf. Model."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/11\/1540\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:33:42Z","timestamp":1760114022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/11\/1540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,16]]},"references-count":99,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["ph17111540"],"URL":"https:\/\/doi.org\/10.3390\/ph17111540","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,16]]}}}